Citigroup Inc. upgraded shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) from a neutral rating to a buy rating in a report released on Monday. They currently have $3.00 price objective on the biotechnology company’s stock.
A number of other equities analysts have also issued reports on CATB. HC Wainwright boosted their target price on shares of Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a buy rating in a research report on Monday, August 14th. Oppenheimer Holdings, Inc. lowered their price target on shares of Catabasis Pharmaceuticals from $9.00 to $4.00 and set an outperform rating on the stock in a report on Tuesday, August 15th. CIBC reissued an outperform rating and issued a $7.00 price target (up previously from $4.00) on shares of Catabasis Pharmaceuticals in a report on Thursday, October 5th. Cowen and Company reissued a market perform rating and issued a $2.00 price target on shares of Catabasis Pharmaceuticals in a report on Friday, October 6th. Finally, Zacks Investment Research lowered shares of Catabasis Pharmaceuticals from a strong-buy rating to a hold rating in a report on Monday, October 16th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Catabasis Pharmaceuticals presently has an average rating of Buy and a consensus target price of $4.82.
Shares of Catabasis Pharmaceuticals (CATB) opened at $1.79 on Monday. Catabasis Pharmaceuticals has a one year low of $1.08 and a one year high of $5.51.
Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.02. The company had revenue of $0.25 million for the quarter. research analysts anticipate that Catabasis Pharmaceuticals will post -1.42 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://transcriptdaily.com/2017/11/23/catabasis-pharmaceuticals-inc-catb-raised-to-buy-at-citigroup-inc.html.
A number of institutional investors have recently added to or reduced their stakes in CATB. Renaissance Technologies LLC acquired a new position in Catabasis Pharmaceuticals during the 1st quarter valued at about $106,000. Oppenheimer & Co. Inc. increased its stake in shares of Catabasis Pharmaceuticals by 33.3% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock valued at $169,000 after acquiring an additional 30,000 shares during the last quarter. Virtu KCG Holdings LLC bought a new stake in shares of Catabasis Pharmaceuticals in the 2nd quarter valued at about $271,000. Finally, Wedbush Securities Inc. increased its stake in shares of Catabasis Pharmaceuticals by 2,368.6% in the 3rd quarter. Wedbush Securities Inc. now owns 251,802 shares of the biotechnology company’s stock valued at $534,000 after acquiring an additional 241,602 shares during the last quarter. Institutional investors own 32.23% of the company’s stock.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.